Letter

Switching statins: NICE tool overestimates benefits of statins

BMJ 2006; 332 doi: 10.1136/bmj.332.7556.1512-b (Published 22 June 2006)
Cite this as: BMJ 2006;332:1512.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. D Graham Mackenzie, specialist registrar in public health (gm@nhs.net)
  1. Public Health Department, NHS Fife, Windygates, Fife KY8 5RG

    EDITOR—Moon and Bogle should be supported in their call to move from branded to generic statins.1 However, by using the costing tool of the National Institute for Health and Clinical Excellence (NICE),2 they have probably overestimated the benefits of statins.

    The 10 year risk thresholds for cardiovascular disease for starting a statin in primary prevention have recently been reduced from 40% to 20%. …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular